Drugs / Autologous humanized anti-CD22 chimeric antigen receptor T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04340167 | May 2020 → Apr 2024 | acute lymphoblastic leukemia | Beijing Boren Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous humanized anti-CD22 chimeric antigen receptor T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04340167 ↗ |
| Modality | Cell therapy | “CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis” NCT04340167 ↗ |
| Target | CD22 | “anti-CD22 chimeric antigen receptor T cells” NCT04340167 ↗ |